Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin

Cavalli, Roberta; Bargoni, Alessandro; Podio, Valerio; Muntoni, Elisabetta; Zara, Gian Paolo; Gasco, Maria Rosa

doi:10.1002/jps.10368

Cited by 116 publications

(45 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well established that oral SLNs facilitate the lymphatic uptake of drugs (eg, lopinavir, tobramycin, and methotrexate), mainly via chylomicron formation. 23,24,43 In particular, tristearin nanoparticles have been reported to be effective in enhancing the lymphatic uptake of oral methotrexate. 24 In vivo pharmacokinetic study in rats Notes: Values were expressed as the mean ± standard deviation except median (ranges) for T max ; n=4.…”

Section: In Situ Closed-loop Study In Ratsmentioning

confidence: 99%

Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake

Cho¹,

Park²,

Yoon³

et al. 2014

IJN

View full text Add to dashboard Cite

Docetaxel is a potent anticancer drug, but development of an oral formulation has been hindered mainly due to its poor oral bioavailability. In this study, solid lipid nanoparticles (SLNs) surface-modified by Tween 80 or D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS 1000) were prepared and evaluated in terms of their feasibility as oral delivery systems for docetaxel. Tween 80-emulsified and TPGS 1000-emulsified tristearin-based lipidic nanoparticles were prepared by a solvent-diffusion method, and their particle size distribution, zeta potential, drug loading, and particle morphology were characterized. An in vitro release study showed a sustained-release profile of docetaxel from the SLNs compared with an intravenous docetaxel formulation (Taxotere®). Tween 80-emulsified SLNs showed enhanced intestinal absorption, lymphatic uptake, and relative oral bioavailability of docetaxel compared with Taxotere in rats. These results may be attributable to the absorption-enhancing effects of the tristearin nanoparticle. Moreover, compared with Tween 80-emulsified SLNs, the intestinal absorption and relative oral bioavailability of docetaxel in rats were further improved in TPGS 1000-emulsified SLNs, probably due to better inhibition of drug efflux by TPGS 1000, along with intestinal lymphatic uptake. Taken together, it is worth noting that these surface-modified SLNs may serve as efficient oral delivery systems for docetaxel.

show abstract

Section: In Situ Closed-loop Study In Ratsmentioning

confidence: 99%

Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake

Cho¹,

Park²,

Yoon³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…The name of drugs and the relevant references are given in Table 1 (9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). As seen in the table the data includes several kind of nanosystems intended for administration via different routes.…”

Section: Datamentioning

confidence: 99%

A Correlative Model to Predict In Vivo AUC for Nanosystem Drug Delivery with Release Rate-Limited Absorption

Barzegar-Jalali

Mohammadi

et al. 2012

J Pharm Pharm Sci

View full text Add to dashboard Cite

-Purpose. Drug release from nanosystems at the sites of either absorption or effect biophase is a major determinant of its biological action. Thus, in vitro drug release is of paramount importance in gaining insight for the systems performance in vivo. Methods. A novel in vitro in vivo correlation, IVIVC, model denoted as double reciprocal area method was presented and applied to 19 drugs from 55 nano formulations with total 336 data, gathered from literature.Results. The proposed model correlated the in vitro with in vivo parameters with overall error of 12.4 ± 3.9%. Also the trained version of the model predicted the test formulations with overall error of 15.8 ± 3.7% indicating the suitability of the approach. A theoretical justification was provided for the model considering the unified classical release laws. Conclusion. The model does not necessitate bolus intravenous drug data and seems to be suitable for IVIVC of drugs with release rate-limited absorption.

show abstract

“…In addition, as compared to liposomes, their production is easily scalable and they offer increased drug protection, as there is limited access of water to the inner lipidic core (Martins et al, 2007, Attama, 2011. These nanoparticles were previously used successfully to improve the bioavailability of distinct drugs, such as idarubicin (Zara et al, 2002), tobramycin (Cavalli et al, 2003) and insulin (Fonte et al, 2012), amongst others.…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%

Natural carriers for application in tuberculosis treatment

Costa

Grenha

2012

Journal of Microencapsulation

View full text Add to dashboard Cite

Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin

Cited by 116 publications

References 22 publications

Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake

Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake

A Correlative Model to Predict In Vivo AUC for Nanosystem Drug Delivery with Release Rate-Limited Absorption

Natural carriers for application in tuberculosis treatment

Contact Info

Product

Resources

About